期刊文献+

HPV6型E7在尖锐湿疣初发与复发组织中的表达 被引量:2

Expression of HPV6-E7 Oncoprotein in Incipient and Relapse Condyloma Acuminatum Tissues
下载PDF
导出
摘要 目的本研究旨在分析HPV6型早期蛋白E7在尖锐湿疣初发、复发与正常组织中的表达情况,以探讨早期蛋白E7在尖锐湿疣病情转归中的生物学意义。方法采用u ltrasensitiveTM s-p免疫组化法对56例初发尖锐湿疣患者的活检组织,35例复发尖锐湿疣患者的活检组织及27例正常宫颈上皮组织中的HPV6型E7蛋白的表达情况进行测定。结果56例初发尖锐湿疣患者HPV6型E7蛋白的阳性表达率为69.5%,35例复发性尖锐湿疣患者的活检组织中HPV6型E7蛋白的阳性表达率为71.4%,27例正常宫颈上皮组织中HPV6型E7蛋白的阳性表达率为0。尖锐湿疣患者初发与复发组织的HPV6型E7蛋白表达和正常宫颈上皮组织相比均有显著性差异(P<0.001)。结论HPV6型早期蛋白E7与尖锐湿疣的发生密切相关,在尖锐湿疣的发展中也起着重要的作用,与其复发存在一定的关系,但没有统计学意义。HPV6型早期蛋白E7与尖锐湿疣的病情转归的联系尚需进一步研究。 Objective This study was designed to determine the expression of HPV6-E7 oneoprotein in normal cervix uteri tissues, incipient condyloma acuminatum tissues and relapse condyloma acuminatum tissues,and to investigate the biological significance of HPV6 - E7 in conversion of condyloma acuminatum. Methods HPV6-E7 was determined using immunohistochenlical staining in normal cervix uteri tissues(27 cases),incipient condyloma acuminatum tissues(56 cases) and relapse condyloma acuminatum tissues(35cases), Results The positive rates of HPV6-E7 in the tissues of normal cervix uteri,incipient eondyloma acuminatum and relapse condyhmm acuminatum were 0.69.5c/c and 71.4%,respeetively. The positive rates of HPV6-E7 in incipient and relapse cnndyloma acuminatum tissues wvere significantly higher than those in normal cervix uteri(P 〈 0. 001 ). Conclusion The results suggest that HPV6-E7 is correlative with the invasion of condyloma acuminatum,and it also plays an important role in the development of cnndyloma acuminatum. Though there is some relation with its relapse, they have no statistical significance. It needs further study for the relation between HPV6-E7 and the conversion of cnndyloma acuminatum.
出处 《中国皮肤性病学杂志》 CAS 北大核心 2005年第12期733-734,共2页 The Chinese Journal of Dermatovenereology
关键词 HPV6 E7 尖锐湿疣 初发 复发 HPV6 E7 Condyloma aeunlinatum incipient relapse
  • 相关文献

参考文献15

  • 1王淼,陈莲凤,宋国兴.外生殖器疣治疗现状与展望[J].临床皮肤科杂志,2002,31(3):196-198. 被引量:19
  • 2田洪青,杜东红,陈树民.尖锐湿疣发病和复发的危险因素研究现状[J].国外医学(皮肤性病学分册),2002,28(5):303-305. 被引量:28
  • 3张明策,刘跃华,刘世德,张宝祥,司静懿,许雪梅,陈莲凤,宋国兴.尖锐湿疣患者人乳头瘤病毒6、11型的检测及L1基因的序列分析[J].中国医学科学院学报,2000,22(5):463-466. 被引量:13
  • 4Labropoulou V,Diakomanolis E,Dailianas S,et al.Typespecific prevalence of genital human papillomavirus in benign,premalignant,and malignant biopsies in patients from greece[J].Sex Trans Dis,1997,24:469-474.
  • 5Frazer IH,Thomas R,Zhou J,et al.Potential strategies utilised by papillomavirus to evade host immunity[J].Immunol Rev,1999,168:131 -132.
  • 6Hiyam E,Kodama T,Shinbara K,et al.Telomerase activity is detected in pancieatic cancer but not in binign tumors[J].Cencer Res,1997,57(2):326 -331.
  • 7Gissmann L,Osen W,Muller M,et al.Therapeutic vaccines for human papillomaviruses[J].Intervirology,2001,44 (2 -3):167-175.
  • 8Chen CH,Ji H,Suh KW,et al.Gene gun-mediated DNA vaccination induces antitumor immunity against human papillomavirus type 16 E7-expressing murine tumor metastaees in the liver and lungs[J].Gene Ther,1999,6(12):1972-1981.
  • 9张炜,伍欣星,谭云,赵旻,丁晓华,邱小萍,戴天力,赵文先.人乳头瘤病毒16型E7DNA疫苗的构建及其诱导特异性淋巴细胞增殖的研究[J].武汉大学学报(医学版),2001,22(2):97-100. 被引量:4
  • 10Tbompson HS,Davies ml,Holding FP,et al.Phase I safety and antigenicity of TA-GW:a recombinant HPV61L2E7 vaccine for the treatment of genital warts[J].Vaccine,1999,17 (1):40 -49.

二级参考文献52

  • 1[1]Handsfield HH.Clinical presentation and natural course of anogenital warts[J].Am J Med, 1997, 102(5A): 16-20.
  • 2[2]Koutsky L.Epidemiology of genital human papillomavirus infection[J], Am J Med, 1997, 102(5A): 3-8.
  • 3[3]Beutner KR, Reitano MV, Richwald GA, et al.External genital warts: report of the American Medical Association Consensus Conference[J].Clin Infect Dis, 1998, 27(4): 796-806.
  • 4[4]Beutner KR,Ferenczy A.Therapeutic approaches to genital warts[J].Am J Med, 1997, 102(5A): 28-37.
  • 5[5]Beutner KR, Wiley DJ, Douglas JM, et al.Genital warts and their treatment[J].Clin Infect Dis, 1999, 28(Suppl 1): S37-56.
  • 6[6]Perry CM, Lamb HM, Topical imiquimod: a review of its use in genital warts[J].Drugs, 1999;58(2):375-390.
  • 7[7]Schneider A.Natural history of genital papillomavirus Infections[J].Inter Virology, 1994, 37(3 4):201-214.
  • 8[8]Phelps WC, Alexander KA.Antiviral therapy for human papillomavirus: rationale and prospects[J].Ann Inter Med, 1995, 123(5): 368-382.
  • 9[9]Malejczyk J, Majewski S, Jablonska S.Cellular immunity in cutaneous and genital HPV infections[J].Clin Dermatol, 1997, 15(2): 261-274.
  • 10[10]Carter JJ, Galloway DA.Humoral immune response to human popillomavirus infection[J].Clin Dermatol, 1997, 15(2): 249-259.

共引文献70

同被引文献12

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部